Shares of Jasper Therapeutics, Inc. (JSPR) tanked over 52% on Wednesday morning after the clinical-stage biotechnology company reported data from BEACON study of Briquilimab in Chronic Spontaneous Urticaria.
JSPR is currently trading at $8.42, down $9.29 or 52.46%, on the Nasdaq. The stock opened its trading at $ 8.74 after closing Tuesday at $17.71. The stock has traded between $6.61 and $31.01 in the past 52-week period.
Briquilimab is a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma.
The company reported preliminary data from Jasper's ongoing BEACON Phase 1b/2a study of subcutaneous briquilimab in adult participants with CSU.
Substantial reductions in UAS7 were reported, with a mean change from baseline at 8 weeks of -26.6 in the 240mg single-dose cohort and multiple dosing regimens at or above 120mg demonstrating UAS7 changes of more than -25 points.
Clinical responses were observed as early as 1-week post-first dose, and Complete Responses were achieved by patients at each therapeutic dose level, most notably, all patients in the 240mg single-dose cohort maintained Complete Responses through the 8-week time-point.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.